Guangzhou Financial Holding Fund Management
VC Fund
Guangzhou, China
Guangzhou Financial Holding Fund Management is a VC fund in Guangzhou focused on Medical and Health Care. Guangzhou Jinkong Fund a subsidiary of state-owned Guangzhou Finance Holdings
- Total investments:
- 10
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Guangzhou Financial Holding Fund Management invests in
Stages Guangzhou Financial Holding Fund Management invests in
Countries Guangzhou Financial Holding Fund Management invests in
Investment Focus
Industry
- Medical 4 (40%)
- Health Care 4 (40%)
- Biotechnology 3 (30%)
- Robotics 2 (20%)
- Medical Device 2 (20%)
Stage
- Seed 3 (30%)
- Series A 3 (30%)
- Series B 2 (20%)
- Angel 1 (10%)
- Venture - Series Unknown 1 (10%)
Country
- China 9 (90%)
- United States 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
GOWIN Semiconductor
|
Founded in 2014, GOWIN Semiconductor Corp., headquartered with major R&D in China, has the vision to accelerate customer innovation world wide with their programmable solutions. They focus on optimizing their products and removing barriers for customers using programmable logic devices. Their commitment to technology and quality enablescustomers to reduce the total cost of ownership from using FPGA on their production boards. Their offerings include a broad portfolio of programmable logic devices, design software, intellectual property (IP) cores, reference designs, and development kits. They strive to serve customers in the consumer, industrial, communication, medical, and automotive markets worldwide. | Venture - Series Unknown / Jul 02, 2026 | |
|
Migos Medical
|
Migos Medical is an innovative medical device company specializing in minimally invasive ophthalmology. Its core technology is based on active cationic polymerization biomaterial technology, which likely enables advanced biomaterials for ophthalmic applications. | Series A / May 20, 2025 | |
Huateng Biotech
|
Huateng Biotech is an outsourcer of life science and pharmaceutical research and development. It focuses on analyzing gene-edited cell models in vitro. | Series B / Sep 23, 2024 | |
Shineyo Medical
|
Shineyo Medical is a provider of minimally invasive cardiovascular interventional treatment devices, focusing on electrophysiology and peripheral intervention. They aim to become a domestic provider of solutions for atrial fibrillation and varicose veins. | $13.9M / Series A / Aug 12, 2024 | |
Sinchoo medical
|
Sinchoo medical is a medical technology company specializing in clinical medicine and public health, focusing on innovative research, technology development, and digital medicine, biomedicine, and public health. | Seed / Jul 03, 2024 | |
Sealien
|
Sealien is a company specializing in the research and development, production, engineering services, and leasing of deep-sea industrial robots and maritime intelligent equipment. The company possesses significant technological strength and innovation skills. | Seed / Jun 26, 2024 | |
ThunderBio Innovation
|
ThunderBio Innovation engages in business includes tumor screening based on the digital biopsy technology of microfluidic chip, etc. | $14M / Series B / Jan 04, 2024 | |
NeuExcell Therapeutics
|
NeuExcell is an early stage gene therapy company focusing on neurodegenerative diseases. We have developed a disruptive neural repair technology that utilizes in vivo astrocyte-to-neuron conversion.Our vision is to improve the quality of life of millions of patients worldwide who are suffering from neurodegenerative conditions by using the powerof gene therapy to restore damaged neural tissue. | $15M / Seed / May 04, 2023 | |
Risong Technology
|
Risong Technology engages in the R&D, designing, manufacturing, application and sales of robot and intelligent equipment. | $25.1M / Series A / Nov 22, 2016 | |
Recomgen Biotech
|
Recomgen Biotech is an innovative biopharmaceutical company that focuses on large-scale serum-free continuous animal cell culture technology and the R&D of new biological drugs. Recomgen Biotech is working on developing rhTNK-tPA, a generation-specific thrombolytic drug that can be injected intravenously in a single dose, making it convenientfor emergency treatment and out-of-hospital thrombolysis as needed. It improves the treatment rate, clinical benefit, and personal and societal medical burdens in patients with acute myocardial infarction who received thrombolytic therapy. | $425K / Angel / Oct 24, 2000 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Guangzhou Financial Holding Fund Management invest in?
Guangzhou Financial Holding Fund Management invests primarily in Medical, Health Care and Biotechnology startups, most often at Seed and Series A stage. Most of the 10 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Guangzhou Financial Holding Fund Management last invest?
The most recent investment recorded for Guangzhou Financial Holding Fund Management closed in Jul 2026. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
